Silco Pharmaceuticals Limited (DSE:SILCOPHL)

Market Cap	1.57B +6.3%
Revenue (ttm)	408.71M -4.6%
Net Income	34.23M -26.5%
EPS	0.33 -26.7%
Shares Out	103.81M
PE Ratio	45.64
Forward PE	n/a
Dividend	0.11 (0.73%)
Ex-Dividend Date	Nov 26, 2026

Volume	433,840
Open	n/a
Previous Close	14.70
Day's Range	14.70 - 15.30
52-Week Range	11.10 - 23.30
Beta	0.35
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 8, 2026

About Silco Pharmaceuticals

Silco Pharmaceuticals Limited engages in manufacturing, distribution, and marketing of finished pharmaceutical products in Bangladesh. It offers products in the therapeutic areas of analgesic and antipyretic, anti-platelet, antiasthmatic, antibiotic, antidepressant, antidiabetic, antiemetic, antifungal, antihistamin, antihypertensive and antianginal, antimicrobial, antiprotozoal, antispasmodic, antiulcerant, anxiolytic, calcium and combinations, central muscle relaxants, diuretics, gastroprokinetic, haematinic, vitamins and minerals, laxatives,...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 313
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SILCOPHL

Financial Performance

In fiscal year 2025, Silco Pharmaceuticals's revenue was 431.54 million, an increase of 5.23% compared to the previous year's 410.10 million. Earnings were 42.65 million, a decrease of -7.04%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 4, 2026

Data Sources Report a data error